Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AstraZeneca
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Incyte Corporation
Eli Lilly and Company
Pfizer
M.D. Anderson Cancer Center
Alterome Therapeutics, Inc.
M.D. Anderson Cancer Center
Hoffmann-La Roche
Pfizer
Incyte Corporation
Tizona Therapeutics, Inc
Genentech, Inc.
Revolution Medicines, Inc.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Pfizer
Bristol-Myers Squibb
Fate Therapeutics
M.D. Anderson Cancer Center
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Pfizer
Shanghai Zhongshan Hospital
Fate Therapeutics
Massachusetts General Hospital
Eli Lilly and Company
Innovent Biologics (Suzhou) Co. Ltd.
Eli Lilly and Company
National Institutes of Health Clinical Center (CC)
Dragonboat Biopharmaceutical Company Limited
M.D. Anderson Cancer Center
Georgetown University
Novartis
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Merck Sharp & Dohme LLC
Masonic Cancer Center, University of Minnesota
GlaxoSmithKline
Yale University
Genentech, Inc.
Bristol-Myers Squibb
University of Chicago
Genentech, Inc.
Merrimack Pharmaceuticals
Eli Lilly and Company
EMD Serono
Novartis
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
Bristol-Myers Squibb